ELIZABETH SHPALL to Neoplasms
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Neoplasms.
Connection Strength
0.638
-
Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781.
Score: 0.092
-
Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant. 2006 Feb; 12(2):113-25.
Score: 0.042
-
Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol. 2004 Nov; 26(1-2):31-56.
Score: 0.038
-
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784.
Score: 0.036
-
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945.
Score: 0.035
-
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
Score: 0.033
-
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol. 2022; 13:1032397.
Score: 0.033
-
The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Semin Oncol Nurs. 2021 12; 37(6):151216.
Score: 0.031
-
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 07; 18(7):435-453.
Score: 0.030
-
Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors? Biol Blood Marrow Transplant. 2020 10; 26(10):1759-1769.
Score: 0.028
-
Autologous stem-cell transplantation for solid tumors in adults. Hematol Oncol Clin North Am. 1999 Oct; 13(5):939-68, vi.
Score: 0.027
-
Chimeric Antigen Receptor T-Cell Therapy. J Natl Compr Canc Netw. 2018 09; 16(9):1092-1106.
Score: 0.025
-
Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. Exp Hematol. 1997 Oct; 25(11):1125-39.
Score: 0.023
-
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer. 2017 Sep 01; 123(17):3367-3376.
Score: 0.023
-
Peripheral blood stem cells for autografting. Annu Rev Med. 1997; 48:241-51.
Score: 0.022
-
Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. J Clin Oncol. 2013 Nov 20; 31(33):4207-14.
Score: 0.018
-
Role of autotransplantation in treatment of other solid tumors. Hematol Oncol Clin North Am. 1993 Jun; 7(3):663-86.
Score: 0.017
-
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed). 2012 01 01; 4(2):520-31.
Score: 0.016
-
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008 Apr 15; 68(8):2961-71.
Score: 0.012
-
Update on understanding the causes of cancer. Compr Ther. 1986 Aug; 12(8):9-14.
Score: 0.011
-
Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplant. 2005 Sep; 36(5):425-30.
Score: 0.010
-
Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. Clin Cancer Res. 1999 Apr; 5(4):747-51.
Score: 0.006
-
Peripheral blood stem cell harvesting and CD34-positive cell selection. Cancer Treat Res. 1997; 77:143-57.
Score: 0.006
-
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. Antiviral Res. 2016 10; 134:58-62.
Score: 0.005
-
Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. J Mol Diagn. 2016 09; 18(5):638-642.
Score: 0.005
-
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol. 1996; 37(6):561-8.
Score: 0.005
-
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol. 1989; 23(6):377-83.
Score: 0.003
-
Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):37-40.
Score: 0.003
-
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res. 1999 Mar; 5(3):501-6.
Score: 0.002
-
Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997 Dec; 3(6):331-40.
Score: 0.001